New obesity injection tested for safety with common heart and cholesterol drugs
NCT ID NCT07128888
Summary
This early-stage study is testing an experimental injection called GZR18 in people who are overweight or obese. The main goals are to see how the injection affects how quickly the stomach empties and whether it changes how the body processes three common medications (digoxin, rosuvastatin, and warfarin). The study will enroll 60 participants and last about 26 weeks for each person.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY OR OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study site 01
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.